Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation

被引:30
作者
Houtenbos, I
Westers, TM
Stam, AGM
de Gruijl, TD
Scheper, RJ
Ossenkoppele, GJ
van de Loosdrecht, AA
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Haematol BR 250, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands
关键词
acute myeloid leukaemia; immunotherapy; antigen presenting cells; serum-free culture;
D O I
10.1007/s00262-003-0389-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose.. Immunotherapy holds promise as a new strategy for the eradication of residual cells in acute myeloid leukaemia (AML). Leukaemic antigen presenting cells (APCs) combining optimal antigen presentation and tumour antigenicity could be used as potent T cell activators. For clinical purposes it is desirable to culture APCs under serum-free conditions. Therefore, we compared morphological, immunophenotypical and functional outcome of the serum-free culture of AML-APCs to their serum-enriched culture. Methods.. AML blasts (n=19) were cultured in the presence of either a cytokine mix or calcium ionophore (CI) for 14 and 2 days, respectively, in FCS-containing medium (FCS), StemSpan serum-free medium (SP) and CellGro serum-free medium (CG). After culture relative yields were calculated and immunophenotypic analysis of APC markers was performed. The mixed leukocyte reaction (MLR) was used to determine T cell stimulating capacity. Results.. Serum-free culture of AML-APCs resulted in comparable morphology, relative yields and immunophenotype to serum-enriched culture. By comparing both serum-free media we observed a trend towards a more mature phenotype of CI-cultured AML-APCs in SP. MLR showed that serum-free cultured cells have equal T cell stimulatory capacity in comparison with serum-enriched culture. Conclusion.. These data show that the serum-free culture of AML-APCs is feasible and that these APCs are comparable to serum-enriched cultured AML-APCs with regard to morphological, immunophenotypical and functional characteristics. These AML-APCs are suitable for the development of active specific immunisation protocols which meet the criteria for good clinical practise (GCP).
引用
收藏
页码:455 / 462
页数:8
相关论文
共 31 条
[1]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[2]  
Boczkowski D, 2000, CANCER RES, V60, P1028
[3]   In vitro culture of acute myelogenous leukemia blasts: A comparison of four different culture media [J].
Bruserud, O ;
Frostad, S ;
Foss, B .
JOURNAL OF HEMATOTHERAPY, 1999, 8 (01) :63-73
[4]   In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media:: Studies of native AML blasts and AML cell lines [J].
Bruserud, O ;
Gjertsen, BT ;
Von Volkman, HL .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (06) :923-932
[5]  
Charbonnier A, 1999, EUR J IMMUNOL, V29, P2567, DOI 10.1002/(SICI)1521-4141(199908)29:08<2567::AID-IMMU2567>3.0.CO
[6]  
2-S
[7]   Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia [J].
Choudhury, A ;
Gajewski, JL ;
Liang, JC ;
Popat, U ;
Claxton, DF ;
Kliche, KO ;
Andreeff, M ;
Champlin, RE .
BLOOD, 1997, 89 (04) :1133-1142
[8]   CD34+ acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells [J].
Cignetti, A ;
Bryant, E ;
Allione, B ;
Vitale, A ;
Foa, R ;
Cheever, MA .
BLOOD, 1999, 94 (06) :2048-2055
[9]   Dendritic cells: Unique leukocyte populations which control the primary immune response [J].
Hart, DNJ .
BLOOD, 1997, 90 (09) :3245-3287
[10]   Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors [J].
Heiser, A ;
Coleman, D ;
Dannull, J ;
Yancey, D ;
Maurice, MA ;
Lallas, CD ;
Dahm, P ;
Niedzwiecki, D ;
Gilboa, E ;
Vieweg, J .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (03) :409-417